Global Enteral Medical Nutrition Market Forecast to 2028 - Featuring Abbott Laboratories, Nestle, DSM and Hormel Foods Among Others - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Enteral Medical Nutrition Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Indication, Nutrition Type, Form, Product, Distribution Channel, and Age Group" report has been added to ResearchAndMarkets.com's offering.

The global enteral medical nutrition market is expected to reach US$ 11,726.37 million by 2028 from US$ 7,803.45 million in 2021; it is expected to grow at a CAGR of 6.0% from 2022 to 2028.

Enteral nutrition (EN) is provided to patients whose energy and nutritional needs cannot be met by a regular food intake. The advantages of enteral intake over parenteral nutrition are well recognized. For most pediatric patients who are dependent on enteral nutrition, an age-adapted standard polymeric formula enriched with fibers is an appropriate choice.

Crohn's disease, gastrointestinal disease due to trauma, bowel obstruction (BO), microscopic colitis, short bowel syndrome, and ulcerative colitis are a few gastrointestinal diseases. According to the article in Heathline, in 2021, around 40% of people across the world were affected by functional gastrointestinal disorder. According to Medscape, in developed countries, the most common cause of small-bowel obstruction (SBO) is intra-abdominal adhesions, accounting for ~65 to 75% of cases, followed by hernias. In contrast, in developing countries, SBO is primarily caused by hernias (30-40%), adhesions (about 30%), and tuberculosis (about 10%).

According to the article published by World Journal of Emergency Surgery, bowel obstruction is an important cause of morbidity and mortality accounting for nearly 30,000 deaths and more than US$3 billion per year in direct medical costs. Bowel obstruction is responsible for ~15% of hospital admissions for acute abdominal pain in the US, and ~?20% of cases need acute surgical care.

Crohn's disease is a complex, long-lasting (chronic) disorder that primarily affects the digestive system. It is most common disease in North America and Western Europe and has a prevalence of 100 to 300 per 100,000 in these regions. According to Medline Plus, more than half a million in North American and Western European people are currently suffering from Crohn's disease.

Patients affected by gastrointestinal disease are at an increased risk of nutritional deterioration due to fasting for the diagnostic tests, therapeutic dietary restriction, and appetite loss due to anorexia or altered nutritional requirement developed by the disease itself. Enteral medical nutrition is preferred for the gastrointestinal disease patients as these patients cannot consume food orally. Therefore, the growing prevalence of gastrointestinal diseases across the world drives the growth of the enteral medical nutrition market.

Market Dynamics

Drivers

• Increase in Prevalence of Cachexia
• Rise in Prevalence of Gastrointestinal Diseases

Restraints

• Complications of Enteral Nutrition

Opportunities

• Use of Next Generation Technology for Proper Enteral Nutrition Feeding

Future Trends

• Developments Related to Enteral Medical Nutrition Products

Companies Mentioned

• Abbott Laboratories
• Nutricia
• Fresenius Kabi AG
• B- Braun Melsungen AG
• NESTLE S. A.
• Meiji Holdings Co. Ltd
• Smartfish AS
• DSM
• Hormel Foods Corporation
• Global Health Products, Inc.

For more information about this report visit https://www.researchandmarkets.com/r/r55xsa.